CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.18 USD | -6.02% |
|
-12.81% | -46.34% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 5.56M | Capitalization | 588M |
|---|---|---|---|---|---|
| Net income 2024 * | -92M | Net income 2025 * | -109M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 258M | Net cash position 2025 * | 181M | EV / Sales 2025 * | 73.3 x |
| P/E ratio 2024 * |
-6.44
x | P/E ratio 2025 * |
-5.77
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | -6.02% | ||
| 1 week | -12.81% | ||
| Current month | -28.60% | ||
| 1 month | -27.46% | ||
| 3 months | -45.33% | ||
| 6 months | -4.92% | ||
| Current year | -46.34% |
1 week
11.68
14.02
1 month
11.6819.04
Current year
11.6826.35
1 year
8.1126.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 12.18 | -6.02% | 2,048,964 |
| 24-04-24 | 12.96 | -2.70% | 931,395 |
| 24-04-23 | 13.32 | 0.00% | 761,527 |
| 24-04-22 | 13.32 | -0.15% | 985,840 |
| 24-04-19 | 13.34 | -4.51% | 1,178,220 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.18
USD
Average target price
34.5
USD
Spread / Average Target
+183.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.34% | 588M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.64% | 22.02B | |
| -17.84% | 20.9B | |
| -9.19% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- CABA Stock
